NICE rejects Janssen's depression spray Spravato for second ...

NICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the company says it could salvage the situation by providing further d

Compass plans $100m IPO to fund magic mushroom depression dr...

UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient that can be found in magic m

Digital depression therapy offers hope during COVID-19 pande...

A new digital therapy is aiming to tackle depression during the COVID-19 pandemic, using a brain stimulation headset and therapy app that claims to have similar beneficial effects to drugs

Orexo buys US rights to GAIA's deprexis digital therapeutic

Sweden's Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to help patients manage their symptoms of depression and one of the most researched

ECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSK

NICE rejects J&J’s Spravato for treatment-resistant depressi...